US midterms and beyond: the outlook for pharma

Episode 19 of the The Pharma Letter Podcast podcast, hosted by Simon Wentworth, titled "US midterms and beyond: the outlook for pharma" was published on November 28, 2022 and runs 18 minutes.

November 28, 2022 ·18m · The Pharma Letter Podcast

0:00 / 0:00

Summary

The outcome of the recent midterm elections in the USA surprised many by returning a Democrat-led Senate, preventing Republicans from gaining control of the next Congress. Analysts, having expected a stronger showing for Republicans, put some of the blame on former president Donald Trump, whose endorsements and active involvement in campaigning were said to frighten off moderates. In this week’s episode of The Pharma Letter Podcast, we are joined by Stephanie Kennan, senior VP for federal pub...

Episode Description

The outcome of the recent midterm elections in the USA surprised many by returning a Democrat-led Senate, preventing Republicans from gaining control of the next Congress.

Analysts, having expected a stronger showing for Republicans, put some of the blame on former president Donald Trump, whose endorsements and active involvement in campaigning were said to frighten off moderates.

In this week’s episode of The Pharma Letter Podcast, we are joined by Stephanie Kennan, senior VP for federal public affairs at McGuireWoods Consulting, for a discussion on the possible implications.

We’ll consider the likely course of future life sciences legislation, in particular the additional provisions which were omitted from the pared back, so-called “skinny” user fee reauthorization in September.

We'll also take a quick look ahead to 2024.

As Florida’s Ron DeSantis basks in the triumph of his gubernatorial campaign, a run at the presidency now looks inevitable, and bookmakers are putting him above Mr Trump as favorite to win power - albeit with a long way to go until polling day.

We’ll discuss what a DeSantis White House might look like for the life sciences industry.

Share this episode

Similar Episodes

EP506: How Other Employers, Shareholders, and Clinics Are Using Price Transparency Data—And It's an Arms Race, With Jerry DiMaso

Apr 9, 2026 ·35m

EP505: The Death of the "What Is Value" Guessing Game for Clinical and Plan Decision-Makers Ready to Move On, With Ahilan Sivaganesan, MD

Apr 2, 2026 ·43m

EP504: A Back-to-Basics Roadmap Through the Perverse Incentives to Advanced Primary Care, With Ryan Jacobs

Mar 26, 2026 ·33m

Insights to Outwit the Hot Mess of the Non-Healthcare Market

Mar 19, 2026 ·19m

EP503: Smart Collaboration With Direct-to-Employer Specialty Care, With Ryan Wells; Leo Spector, MD, MBA; and Adam Stavisky

Mar 12, 2026 ·46m

EP502: How Some Pretty Wild Medicare Fraud Sabotages ACOs and Also Independent Practices and Could Cost Plan Sponsors Such as Self-insured Employers a Lot of Zeros Downstream, With Brian Machut

Mar 5, 2026 ·38m

Similar Podcasts

The Pharmadelic Experience The Pharmadelic Experience The Pharmadelic Experience podcast explores career opportunities in the pharma sector. Each episode will focus on a different career field, so you can learn what they do, how they got there and what challenges they have encountered along the way. For inquiries email: [email protected] Pharma Marketing Playbook: Data, GenAI, and Beyond Saumya Prakash, Multiplier AI Discover the transformative power of GenAI, Data Analytics, Social Intelligence, and Physician Influencer Marketing that is shaping the future of pharma marketing. Join us, as we pave the pathway to a novel pharma marketing landscape, bringing to you conversations that meet at the intersection of technology and marketing.Hosted by Saumya Prakash, Co-Founder Multiplier AI Solutions, this podcast is spearheading the dialogues on disruptions in pharma marketing.Know more about us at: https://multiplierai.co/ Deep Pharma Intelligence Deep Pharma Intelligence Deep Pharma Intelligence (DPI) is a leading strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, BioTech, and Healthcare Tech industries. DPI is producing regular analytical reports on major areas of high-potential in the pharmaceutical and healthcare industries, maintaining ratings of companies and governments based on their innovation potential and business activity in the BioTech space, and providing strategic consulting and investment intelligence services to top-tier clients. Uncategorized – The Race to Value Podcast™ Institute for Advancing Health Value We are in a race to make health value work in the country. The imperative to drive health value is no longer an optional transition. The unsustainable upward cost trajectory of U.S. healthcare spending, coupled with declining outcomes and disparity gaps, are leaving vulnerable populations woefully underserved. To win the “race to value” we me must have disruptive innovation, spirited collaboration, democratized knowledge, realignment of the healthcare workforce towards value-based care competencies, and a collective moral purpose to reform our industry.In this podcast, leaders from the Accountable Care Learning Collaborative (ACLC) interview the top healthcare executives and entrepreneurs to discuss healthcare’s value economy. Race to Value is the show to connect you with other healthcare leaders working to create better value in health, including provider organizations —hospitals and health systems, physician practices, and post-acute providers — health plans, pharma

URL copied to clipboard!